The American Society of Hematology (ASH) Annual Meeting & Exposition began December 5 with numerous presentations, abstracts and posters.

Roche Group member Genentech announced that new data from the pivotal Phase III MURANO and CLL14 studies support the efficacy of fixed-duration, chemotherapy-free Venclexta (venetoclax)-based combinations in certain people with chronic lymphocytic leukemia (CLL) and provide more evidence on the potential value of minimal residual disease.

Bristol Myers Squibb said the U.S. health regulator deferred a decision on an experimental blood cancer therapy that the company acquired in the $74 billion buyout of Celgene due to coronavirus-related travel restrictions.

The U.S. Food and Drug Administration issued a Complete Response Letter (CRL) for Sanofi’s blood cancer treatment sutimlimab.

AstraZeneca’s blood cancer treatment Calquence failed to improve survival rates and prevent lung failure in patients hospitalized with symptoms of Covid-19, the drugmaker said, citing results from mid-stage trials.

South San Francisco-based Allogene Therapeutics released some early data from the company’s UNIVERSAL clinical trial of ALLO-715 for relapsed/refractory multiple myeloma.

ADC Therapeutics SA announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration for loncastuximab tesirine (Lonca) for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

Gilead Sciences Inc. is nearing a deal to buy biopharmaceutical company Immunomedics Inc. for more than $20 billion in a deal that would further expand Gilead’s portfolio of cancer treatments, the Wall Street Journal reported on Saturday.

Research published in Lancet Oncology analyzed how the risk of death from Covid-19 varies by tumor subtype and patient demographics.

Novartis drug candidate asciminib notched a trial win against Pfizer’s Bosulif as the Swiss drugmaker pushes to expand medicines for chronic myeloid leukemia in patients for whom other treatments stopped working.